Published in BMJ on October 03, 2012
Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet (2015) 4.44
Public health and international drug policy. Lancet (2016) 1.71
Addressing the HIV/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach. Am J Public Health (2014) 1.62
Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study. Lancet HIV (2015) 1.48
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of Care. Curr HIV/AIDS Rep (2015) 1.02
Human resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services. Bull World Health Organ (2013) 1.01
Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One (2014) 0.97
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med (2014) 0.96
Tailored combination prevention packages and PrEP for young key populations. J Int AIDS Soc (2015) 0.93
Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med (2014) 0.91
Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ (2013) 0.91
The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet (2016) 0.90
Effect of rapid HIV testing on HIV incidence and services in populations at high risk for HIV exposure: an equity-focused systematic review. BMJ Open (2014) 0.86
Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS One (2014) 0.86
Global HIV epidemiology: A guide for strategies in prevention and care. Curr HIV/AIDS Rep (2014) 0.85
Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction (2015) 0.84
Scaling up opioid dependence treatment in low- and middle-income settings. Bull World Health Organ (2013) 0.84
"In their perception we are addicts": social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam. Int J Drug Policy (2014) 0.84
HIV Care Continuum Among Men Who Have Sex With Men and Persons Who Inject Drugs in India: Barriers to Successful Engagement. Clin Infect Dis (2015) 0.83
Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open (2015) 0.82
Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period. PLoS One (2014) 0.82
Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators. AIDS Behav (2016) 0.82
In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine. Drugs (Abingdon Engl) (2016) 0.81
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med (2016) 0.80
The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend (2014) 0.80
Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users. Addict Behav (2015) 0.80
Geographic variability in HIV and injection drug use in Ukraine: implications for integration and expansion of drug treatment and HIV care. Int J Drug Policy (2014) 0.80
Combined prevention for persons who inject drugs in the HIV epidemic in a transitional country: the case of Tallinn, Estonia. AIDS Care (2014) 0.79
The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care. J Subst Abuse Treat (2014) 0.79
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. R I Med J (2013) (2014) 0.79
Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base? Addiction (2014) 0.78
Differential risk factors for HIV drug and sex risk-taking among non-treatment-seeking hospitalized injection drug users. AIDS Behav (2015) 0.78
Methadone Maintenance Treatment Promotes Referral and Uptake of HIV Testing and Counselling Services amongst Drug Users and Their Partners. PLoS One (2016) 0.78
Messaging to Increase Public Support for Naloxone Distribution Policies in the United States: Results from a Randomized Survey Experiment. PLoS One (2015) 0.78
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev (2016) 0.78
Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United States. PLoS One (2015) 0.77
Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. BMC Infect Dis (2014) 0.77
Increasing prevalence of HIV infection among first time clients in Italian drug treatment services - is it sexual transmission? BMC Infect Dis (2015) 0.77
Comparison of outcomes after 3-month methadone maintenance treatment between heroin users with and without HIV infection: a 3-month follow-up study. Harm Reduct J (2015) 0.77
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr (2015) 0.77
Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. Curr HIV Res (2014) 0.76
The role of opioid substitution treatment in reducing HIV transmission. BMJ (2012) 0.76
Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study. Subst Abuse Treat Prev Policy (2014) 0.75
Cross-sectional assessments of participants' characteristics and loss to follow-up in the first Opioid Substitution Therapy Pilot Program in Kabul, Afghanistan. Harm Reduct J (2015) 0.75
Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction (2016) 0.75
A comprehensive approach to addiction medicine as an appropriate response to the HIV epidemic among drug users. J Food Drug Anal (2013) 0.75
'Crisis' and 'everyday' initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug Alcohol Rev (2016) 0.75
Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization. J Subst Abuse Treat (2016) 0.75
Recreational Drug Use among Chinese MSM and Transgender Individuals: Results from a National Online Cross-Sectional Study. PLoS One (2017) 0.75
Methadone treatments in a Swiss region, 2001-2008: a registry-based analysis. BMC Psychiatry (2012) 0.75
HIV Risk Behavior Among Methamphetamine Users Entering Substance Abuse Treatment in Cape Town, South Africa. AIDS Behav (2016) 0.75
Opioid substitution therapy is associated with decreased HIV transmission among people who inject drugs. Evid Based Med (2013) 0.75
A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011. Int J Drug Policy (2016) 0.75
Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis (2017) 0.75
HIV prevention, treatment, and care for people who inject drugs. J Infect Dis (2013) 0.75
Emergence of methadone as a street drug in St. Petersburg, Russia. Int J Drug Policy (2015) 0.75
Current and recent drug use intensifies sexual and structural HIV risk outcomes among female sex workers in the Russian Federation. Int J Drug Policy (2015) 0.75
A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict (2016) 0.75
The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evid Based Med Public Health (2016) 0.75
Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences. AIDS Care (2017) 0.75
Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Rev (2017) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA (1998) 26.79
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
Cohort Profile: the Whitehall II study. Int J Epidemiol (2004) 7.63
Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet (2012) 6.36
Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr (1993) 5.08
HIV and risk environment for injecting drug users: the past, present, and future. Lancet (2010) 4.77
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (2008) 4.74
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS (1994) 3.67
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ (2010) 3.59
Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction (2010) 3.41
Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet (2010) 3.29
Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend (2000) 3.18
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction (2011) 2.95
HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health (2000) 2.74
HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction (1999) 2.67
Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol (2010) 2.65
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ (1998) 2.64
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction (2008) 2.46
Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction (2006) 2.46
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction (2012) 2.45
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29
HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS (1994) 2.11
Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev (2011) 2.09
Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction (2010) 2.09
The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction (2012) 2.06
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS (2001) 1.80
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction (2008) 1.76
Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction (2003) 1.58
A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. AIDS (2009) 1.55
Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health (1998) 1.54
Maintenance drugs to treat opioid dependence. BMJ (2012) 1.51
One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend (2005) 1.31
Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill (2011) 1.30
Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS (2007) 1.29
Marked ethnic differences in HIV prevalence and risk behaviors among injection drug users in Dushanbe, Tajikistan, 2004. Drug Alcohol Depend (2006) 1.27
High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia. Int J STD AIDS (2007) 1.22
HIV incidence among high-risk Puerto Rican drug users: a comparison of East Harlem, New York, and Bayamón, Puerto Rico. J Acquir Immune Defic Syndr (2004) 1.20
Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care (1994) 1.17
Do drug users in China who frequently receive detoxification treatment change their risky drug use practices and sexual behavior? Drug Alcohol Depend (2006) 1.15
Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care (1992) 1.14
Mortality and increasing drug use in Edinburgh: implications for HIV epidemic. Scott Med J (1990) 1.08
Risk factors for HIV-1 seroconversion among injection drug users: a case-control study. Am J Public Health (1995) 1.05
HIV-1 incidence among opiate users in northern Thailand. Am J Epidemiol (1999) 1.04
Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin. J Epidemiol Community Health (2003) 0.98
Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health (2009) 0.98
Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction (2009) 0.96
Methadone treatment in the Scottish context: outcomes of a community-based service for drug users in Lothian. Drug Alcohol Depend (1998) 0.96
Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes. Eur Addict Res (2009) 0.94
Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in montreal, Canada: a 16-year longitudinal study. Am J Epidemiol (2011) 0.94
Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995 to 1998. J Acquir Immune Defic Syndr (2000) 0.93
HIV among injecting drug users in Europe: increasing trends in the East. Euro Surveill (2008) 0.92
Coverage of HIV prevention programmes for injection drug users: confusions, aspirations, definitions and ways forward. Int J Drug Policy (2007) 0.91
Scale-up of opioid substitution therapy in India: opportunities and challenges. Int J Drug Policy (2012) 0.85
[Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France]. Rev Epidemiol Sante Publique (2006) 0.85
The impact of sex partners' HIV status on HIV seroconversion in a prospective cohort of injection drug users. J Acquir Immune Defic Syndr (2006) 0.84
Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J Acquir Immune Defic Syndr (1992) 0.80
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet (2013) 16.76
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Adverse health effects of non-medical cannabis use. Lancet (2009) 6.25
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (2011) 6.21
Global overview of injecting drug use and HIV infection among injecting drug users. AIDS (2004) 5.45
How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do? Addiction (2010) 5.08
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ (2010) 3.59
Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology (2013) 3.54
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet (2010) 3.29
Cannabis use and mental health in young people: cohort study. BMJ (2002) 3.26
Health of the world's adolescents: a synthesis of internationally comparable data. Lancet (2012) 3.17
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction (2011) 2.95
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med J Aust (2013) 2.71
Understanding polydrug use: review of heroin and cocaine co-use. Addiction (2003) 2.68
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.56
Methods to recruit hard-to-reach groups: comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health (2006) 2.52
2011 SOSORT guidelines: Orthopaedic and Rehabilitation treatment of idiopathic scoliosis during growth. Scoliosis (2012) 2.49
Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction (2006) 2.46
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction (2012) 2.45
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
The ratio of non-fatal to fatal heroin overdose. Addiction (2003) 2.38
If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction (2009) 2.25
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction (2007) 2.20
Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction (2010) 2.14
Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol (2013) 2.08
Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction (2006) 2.06
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health (2005) 2.01
Braces for idiopathic scoliosis in adolescents. Cochrane Database Syst Rev (2010) 1.97
Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction (2007) 1.95
Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ (2013) 1.95
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction (2003) 1.91
Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol (2008) 1.90
Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction (2006) 1.87
The increasing mortality burden of liver disease among opioid-dependent people: cohort study. Addiction (2011) 1.87
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol (2003) 1.84
Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction (2007) 1.81
Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol (2006) 1.78
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood (2013) 1.74
Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health (2005) 1.73
High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer (2012) 1.71
Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr (2005) 1.69
Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev (2008) 1.68
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry (2010) 1.66
Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 1.63
The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain (2015) 1.62
Adolescent alcohol and tobacco use and early socioeconomic position: the ALSPAC birth cohort. Pediatrics (2011) 1.60
Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry (2007) 1.59
Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol (2004) 1.57
Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health (2007) 1.57
Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Addiction (2013) 1.56
The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. BMC Psychiatry (2011) 1.54
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Depend (2006) 1.51
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol (2011) 1.50
Opioid dependence latent structure: two classes with differing severity? Addiction (2010) 1.49
Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. Pain Med (2014) 1.49
Cannabis dependence in young adults: an Australian population study. Addiction (2002) 1.47
A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS (2008) 1.47
Comparison of HIV-specific CD8 T-cell responses among uninfected individuals exposed to HIV parenterally and mucosally. AIDS (2005) 1.47
Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors. Clin Immunol (2012) 1.47
Braces for idiopathic scoliosis in adolescents. Spine (Phila Pa 1976) (2010) 1.46
Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev (2008) 1.44
Exposure to opioid maintenance treatment reduces long-term mortality. Addiction (2008) 1.44
Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. CMAJ (2004) 1.44
Trends in deaths related to drug misuse in England and Wales, 1993-2004. Health Stat Q (2006) 1.43
Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev (2011) 1.40
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
UK classification of cannabis: is a change needed and why? Lancet (2007) 1.38
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Intrauterine exposure to alcohol and tobacco use and childhood IQ: findings from a parental-offspring comparison within the Avon Longitudinal Study of Parents and Children. Pediatr Res (2008) 1.38